

The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the quarter ended September 30, 2007, compared with the corresponding period of the prior year.

Merck & Co., Inc.
Consolidated Results
(In Millions Except Earnings per Common Share)
Quarter Ended September 30
(Unaudited)

	<u>2007</u>	<u>2006</u>	<u>% Change</u>
Sales	\$6,074.1	\$5,410.4	12%
Costs, Expenses and Other			
Materials and production ⁽¹⁾	1,517.7	1,544.1	(2)
Marketing and administrative ⁽²⁾	1,951.4	2,370.6	(18)
Research and development ⁽³⁾	1,440.5	945.4	52
Restructuring costs ⁽⁴⁾	49.3	49.6	(1)
Equity income from affiliates	(768.5)	(595.4)	29
Other (income) expense, net ⁽⁵⁾	(180.9)	(134.7)	34
Income Before Taxes	2,064.6	1,230.8	68
Taxes on Income	539.1	290.2	
Net Income	\$1,525.5	\$940.6	62
Average Shares Outstanding			
Assuming Dilution	2,192.8	2,185.7	
Earnings per Common Share			
Assuming Dilution	\$0.70	\$0.43	63

(1) Includes restructuring costs of \$128.8 million in the third quarter of 2007 and \$199.6 million in the third quarter of 2006 primarily related to accelerated depreciation and asset impairment costs associated with Merck's global restructuring program announced in November 2005.

(2) Includes the impact of reserving an additional \$70 million in the third quarter of 2007 and \$598 million in the third quarter of 2006 solely for future VIOXX legal defense costs.

(3) Includes acquired research expense of \$325.1 million in the third quarter of 2007 resulting from the acquisition of NovaCardia, Inc.

(4) Restructuring costs in 2007 and 2006 represent separation and other related costs associated with the global restructuring program.

(5) The increase primarily reflects the favorable impact of a net gain from the settlements of certain patent disputes.

The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the nine months ended September 30, 2007, compared with the corresponding period of the prior year.

Merck & Co., Inc.
Consolidated Results
(In Millions Except Earnings per Common Share)
Nine Months Ended September 30
(Unaudited)

	<u>2007</u>	<u>2006</u>	<u>% Change</u>
Sales	\$17,954.8	\$16,591.9	8%
Costs, Expenses and Other			
Materials and production ⁽¹⁾	4,595.9	4,332.0	6
Marketing and administrative ⁽²⁾	5,837.2	5,819.6	--
Research and development ⁽³⁾	3,501.0	3,059.9	14
Restructuring costs ⁽⁴⁾	170.9	86.5	98
Equity income from affiliates	(2,180.2)	(1,710.2)	27
Other (income) expense, net ⁽⁵⁾	(521.2)	(305.4)	71
Income Before Taxes	6,551.2	5,309.5	23
Taxes on Income	1,644.9	1,349.6	
Net Income	\$4,906.3	\$3,959.9	24
Average Shares Outstanding			
Assuming Dilution	2,187.4	2,188.5	
Earnings per Common Share			
Assuming Dilution	\$2.24	\$1.81	24

(1) Includes restructuring costs of \$365.6 million in the first nine months of 2007 and \$572.1 million in the first nine months of 2006 primarily related to accelerated depreciation and asset impairment costs associated with Merck's global restructuring program announced in November 2005.

(2) Includes the impact of reserving an additional \$280 million in the first nine months of 2007 and \$598 million in the first nine months of 2006 solely for future VIOXX legal defense costs.

(3) Includes acquired research expense of \$325.1 million in 2007 resulting from the acquisition of NovaCardia, Inc. and \$296.3 million in 2006 related to the acquisition of GlycoFi, Inc. Research and development expenses in 2006 also include restructuring costs of \$55.4 million related to accelerated depreciation associated with the global restructuring program.

(4) Restructuring costs in 2007 and 2006 represent separation and other related costs, as well as gains on the sales of facilities in 2006, associated with the global restructuring program.

(5) The increase primarily reflects the favorable impact of gains on sales of assets and product divestitures, as well as a net gain on the settlements of certain patent disputes.